Clinical trials: Nonsmall Cell Lung Cancer Stage III
Carcinoma, Non-Small-Cell Lung
Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer
This study combines nelfinavir (NFV) with radiation therapy and chemotherapy as a treatment for non-small cell lung cancer (NSCLC) who are considered candidates for pre-operative treatment.
- Trial name
- NCT00791336
- Testing
- Nelfinavir
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Iowa
Carcinoma, Non-Small-Cell Lung
A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)
Evaluation of gemcitabine and cisplatin in combination with either sorafenib or placebo for the treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC)
- Trial name
- NEXUS (NCT00449033)
- Testing
- Sorafenib (Nexavar, BAY43-9006), Gemcitabine, Cisplatin
- Where
- 122 sites in Austria, Belgium and 16 more
- Volunteers
- 904 people
- Sponsor
- Bayer
Carcinoma, Non-Small-Cell Lung
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
This randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared with platinum-based in the adjuvant setting.
- Trial name
- NCT03456076
- Testing
- Alectnib, Cisplatin, Vinorelbine
- Where
- 114 sites in United States, Australia and 25 more
- Volunteers
- 257 people
- Sponsor
- Hoffmann-La Roche
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
This randomized, open-label study will evaluate the efficacy and safety of atezolizumab compared with chemotherapy consisting of a platinum agent (cisplatin or carboplatin per investigator discretion) combined with either…
- Trial name
- NCT02409342
- Testing
- Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody, Carboplatin, Cisplatin
- Where
- 142 sites in United States, Brazil and 17 more
- Volunteers
- 572 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer, Carcinoma, Non-Small-Cell Lung
Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC
The purpose of this study is to assess how well this particular combination of chemotherapy, radiation and surgery works to help people with locally advanced lung cancer, how well PET scans indicates whether someone has responded…
- Trial name
- NCT00238615
- Testing
- Docetaxel, Carboplatin, Radiation therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Stanford University
Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable)…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT02498613
- Testing
- 18F-Fluoromisonidazole, Cediranib Maleate, Laboratory Biomarker Analysis
- Where
- 16 sites in United States, Canada
- Volunteers
- 122 people
- Sponsor
- National Cancer Institute (NCI)
Stage IIIB or IV Non-Small Cell Lung Cancer
A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
This Phase III clinical trial which incorporates an initial Phase II component will determine the survival of advanced Non-small cell lung cancer patients when treated with MK0683 and paclitaxel plus carboplatin
- Trial name
- NCT00473889
- Testing
- vorinostat, Comparator: paclitaxel, Comparator: carboplatin
- Volunteers
- 253 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer
Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00281827
- Testing
- carboplatin, gemcitabine hydrochloride, thalidomide
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lung Cancer
Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00278148
- Testing
- carboplatin, Erlotinib, paclitaxel
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Nathan Pennell, MD, PhD
Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
This randomized phase I/II trial is studying the side effects and best dose of cixutumumab and to see how well erlotinib hydrochloride works when given together with or without cixutumumab in treating patients with stage III or…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00778167
- Testing
- cixutumumab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have…
- Conditions
- AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma
- Trial name
- NCT02595866
- Testing
- Antiretroviral Therapy, Biopsy, Biospecimen Collection
- Where
- 12 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Non - Small Cell Lung Cancer NSCLC
A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 (durvalumab) versus Standard of Care in NSCLC patients with PD-L1 positive tumours and the combination of…
- Trial name
- ARCTIC (NCT02352948)
- Testing
- MEDI4736 (durvalumab), Vinorelbine, Gemcitabine
- Where
- 201 sites in United States, Australia and 24 more
- Volunteers
- 597 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer (NSCLC)
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer…
- Trial name
- SKYSCRAPER-03 (NCT04513925)
- Testing
- Atezolizumab, Tiragolumab, Durvalumab
- Where
- 189 sites in United States, Argentina and 24 more
- Volunteers
- 829 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that…
- Conditions
- Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV
- Trial name
- NCT05014815
- Testing
- Ociperlimab, Tislelizumab, Carboplatin
- Where
- 64 sites in United States, Australia and 6 more
- Volunteers
- 272 people
- Sponsor
- BeiGene
Carcinoma, Non-Squamous Non-Small Cell Lung
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This randomized Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+nab-paclitaxel…
- Trial name
- IMpower130 (NCT02367781)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin, Nab-Paclitaxel
- Where
- 132 sites in United States, Belgium and 6 more
- Volunteers
- 723 people
- Sponsor
- Hoffmann-La Roche
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Non-Small Cell Lung Cancer
Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer
This is a Phase II, open-label trial of Taxotere® + ZD1839 in elderly patients with Stage III-b or IV NSCLC who have received no prior chemotherapy for metastatic disease.
- Trial name
- NCT00231465
- Testing
- docetaxel (Taxotere®), ZD1839
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how…
- Trial name
- NCT02864992
- Testing
- Tepotinib
- Where
- 176 sites in United States, Austria and 13 more
- Volunteers
- 337 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer
Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery
This phase II trial studies how well giving a hypofractionated boost to the primary tumor before standard chemotherapy and radiation therapy works in treating patients with stage II or III non-small cell lung cancer that cannot…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
- Trial name
- NCT02262325
- Testing
- hypofractionated radiation therapy, cisplatin, etoposide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Carcinoma, Non-Small-Cell Lung
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
The present trial will investigate the efficacy and safety of nintedanib in combination with docetaxel as compared to placebo in combination with docetaxel in patients with stage IIIB/IV or recurrent NSCLC of adenocarcinoma…
- Trial name
- NCT02231164
- Testing
- docetaxel, nintedanib
- Where
- 13 sites in United States, Georgia and 1 more
- Volunteers
- 12 people
- Sponsor
- Boehringer Ingelheim